Sunitinib (SUTENT) is a multitargeted inhibitor of VEGF, PDGFR, and FLT-3 that has been approved for advanced RCC (renal cell cancer) (60). The gene discussed is PDGFRB; the disease is renal cell adenocarcinoma.